• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Lee S. Rosen, David Gordon, +10 authors Y Ambros
  • Medicine
  • Cancer journal
  • 2001
  • PURPOSE Zoledronic acid, a new and more potent bisphosphonate, was compared with pamidronate, the current standard treatment for patients with osteolytic or mixed bone metastases/lesions. PATIENTSExpand
  • Lee S. Rosen, David Gordon, +9 authors John J. Seaman
  • Medicine
  • Cancer
  • 2003 (First Publication: 15 October 2003)
  • BACKGROUND The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breastExpand
  • Lee S. Rosen, David Gordon, +9 authors John J. Seaman
  • Medicine
  • Cancer
  • 2004 (First Publication: 15 June 2004)
  • BACKGROUND The authors previously reported the efficacy of a dose of 4 mg of zoledronic acid in reducing skeletal complications in patients with bone metastases secondary to lung carcinoma and otherExpand
  • Amita Patnaik, Lee S. Rosen, +21 authors Geoffrey I. Shapiro
  • Biology, Medicine
  • Cancer discovery
  • 2016 (First Publication: 23 May 2016)
  • UNLABELLED We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 andExpand
  • Lee S. Rosen, David Gordon, +9 authors John J. Seaman
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2003 (First Publication: 15 August 2003)
  • PURPOSE To assess the efficacy and safety of zoledronic acid in patients with bone metastases secondary to solid tumors other than breast or prostate cancer. PATIENTS AND METHODS Patients wereExpand
  • Brett E. Houk, Carlo L. Bello, Bill Poland, Lee S. Rosen, George D. Demetri, Robert J Motzer
  • Medicine
  • Cancer Chemotherapy and Pharmacology
  • 2009 (First Publication: 1 July 2010)
  • PurposeIn this pharmacokinetic/pharmacodynamic meta-analysis, we investigated relationships between clinical endpoints and sunitinib exposure in patients with advanced solid tumors, includingExpand
  • R. Herbst, D. Hong, +11 authors L. Rosen
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2009 (First Publication: 20 July 2009)
  • PURPOSE AMG 386 is an investigational peptide-Fc fusion protein (ie, peptibody) that inhibits angiogenesis by preventing the interaction of angiopoietin-1 and angiopoietin-2 with their receptor,Expand